MediMabBio to Speak at ACCESS CHINA Partnering Forum

December 23rd, 2024 (Shanghai) — We are glad to announce that Dr. Eunhyuk Chang, the Chief Strategy Officer of MediMabBio, will be presenting at the ACCESS CHINA Partnering Forum @ JPM on January 7th-9th, and 21st-23rd, 2025. ACCESS CHINA Biotech Forum is the largest corporate access event between Asia and the Western biopharma industry.

About MediMabBio

MediMabBio is a biotech company founded in 2017, specializing in the development of cutting-edge immuno-oncology and autoimmune disease therapies. The company focuses on antibody and cytokine fusion protein platforms and is advancing a robust pipeline, including its lead programs MFA011 (eIL-15/aTIGIT fusion protein) and MFA031 (eIL-10/aTIGIT fusion protein).

About the speaker

Eunhyuk Chang, Chief Strategy Officer of MediMabBio, is a seasoned R&BD expert with extensive experience in global strategy and business development. With a strong academic background, including a Ph.D. in Neuroscience from the University of Oxford, and professional experience at companies like Samsung Biologics and SK Biopharm, he is driving MediMabBio’s mission to innovate and commercialize transformative therapies.

About ACCESS CHINA Partnering Forum

ACCESS CHINA Partnering Forum @ JPM is scheduled to be held on January 7th-9th, and 21st-23rd, 2025, via Zoom webinar. This event helps biotechs/pharmas efficiently present their assets in front of 500+ healthcare companies and VCs online. During the event, the audience can have access to innovative pharma and healthcare products from worldwide.

Conference Name: ACCESS CHINA Partnering Forum

Date & Time: January 7-9 (Live), and 21-23(VoD), 2025, China time

Content: Keynote Speeches, Panel Discussion, Company Presentations, ChemPartner-ACCESS CHINA Dinner Reception

Scale: Expected 500+ participants Online; 100 company roadshows

Participants: Pharma/Biotech senior management and BDs

View more information at https://biotochina.org/